SCHEMBL520385

SCHEMBL520385

CC(=O)Nc1cccc(Nc2ncc3ccc(-c4cccc(NS(C)(=O)=O)c4)n3n2)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.60
PTK2 Q05397 5/20 0.60
PIP4K2A P48426 2/20 0.52
PIP4K2B P78356 2/20 0.52
DYRK3 O43781 2/20 0.52
CCNT1 O60563 2/20 0.52
CCNA2 P20248 2/20 0.52
CDK2 P24941 2/20 0.52
CDK9 P50750 2/20 0.52
CDK5 Q00535 2/20 0.52
DYRK1A Q13627 2/20 0.52
CDK5R1 Q15078 2/20 0.52
DYRK2 Q92630 2/20 0.52
DYRK1B Q9Y463 2/20 0.52
FYN P06241 7/20 0.47
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CG P48736 1/20 0.47
JAK3 P52333 1/20 0.46
INSR P06213 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521743 0.87 JAK2 (0.49) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL521130 0.86 DYRK3 (0.52) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL522065 0.85 ALK (0.61) JAK2PTK2PIP4K2APIP4K2BDYRK3
SCHEMBL522375 0.83 JAK2 (0.48) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL2506839 0.83 JAK2 (0.48) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL522376 0.83 JAK2 (0.48) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL2506844 0.83 JAK2 (0.48) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL521509 0.83 JAK2 (0.65) JAK2PTK2DYRK3CCNT1CCNA2
SCHEMBL521007 0.82 JAK2 (0.59) JAK2PTK2JAK3INSRALK
SCHEMBL521868 0.82 INSR (0.49) JAK2PTK2DYRK3CCNT1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP claimed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US claimed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US claimed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP claimed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO claimed
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 JAK2 1/4885PTK2 592/4885PIP4K2A 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.